---
title: Evolution from generic drugs to innovation
videoId: WkylI-78U6c
---

From: [[asianometry]] <br/> 

India's economy is predominantly service-based, with pharmaceuticals being a significant exception to this trend <a class="yt-timestamp" data-t="00:00:03">[00:00:03]</a>. As of 2020, India boasts the third-largest pharmaceutical industry globally by volume and the eleventh largest by value, demonstrating rapid growth <a class="yt-timestamp" data-t="00:00:12">[00:00:12]</a>. The nation is the world's leading provider of generic drugs, with the United States relying on India for 40% of its generics <a class="yt-timestamp" data-t="00:00:22">[00:00:22]</a>. In 2020, India's pharmaceutical exports exceeded imports by $16 billion <a class="yt-timestamp" data-t="00:00:30">[00:00:30]</a>. These exports adhere to the stringent standards and regulations of numerous countries worldwide <a class="yt-timestamp" data-t="00:00:35">[00:00:35]</a>. The [[history_of_indias_pharmaceutical_industry | history of this industry]] illustrates its transformation from merely copying existing drugs to becoming a global leader across the entire value chain <a class="yt-timestamp" data-t="00:00:46">[00:00:46]</a>.

## Early Challenges and Foreign Dominance (Pre-1970)

The journey of India's pharmaceutical industry began in 1947 with India's independence <a class="yt-timestamp" data-t="00:01:19">[00:01:19]</a>. At this time, millions of Indians lacked access to essential drugs, and the country's drug industry was almost entirely under foreign control <a class="yt-timestamp" data-t="00:01:22">[00:01:22]</a>. Eight of the top ten firms were Western multinationals, primarily from the UK, France, and Germany, collectively holding a 90% market share <a class="yt-timestamp" data-t="00:01:33">[00:01:33]</a>. Domestic Indian companies largely focused on marketing and distributing drugs produced by others rather than creating their own <a class="yt-timestamp" data-t="00:01:42">[00:01:42]</a>.

As a result, nearly every drug consumed by Indians had to be imported, leading to some of the highest domestic drug prices globally <a class="yt-timestamp" data-t="00:01:50">[00:01:50]</a>. Approximately 99% of these drugs were protected by patents, effectively limiting access to the wealthy <a class="yt-timestamp" data-t="00:01:57">[00:01:57]</a>. The Indian government made several attempts to address this over-reliance on foreign drug imports <a class="yt-timestamp" data-t="00:02:05">[00:02:05]</a>:
*   In 1954, Hindustan Antibiotics Limited (HAL), a public sector pharmaceutical firm, was established <a class="yt-timestamp" data-t="00:02:14">[00:02:14]</a>.
*   A few years later, Indian Drugs and Pharmaceuticals Limited was founded in cooperation with the Soviets <a class="yt-timestamp" data-t="00:02:22">[00:02:22]</a>.

A pivotal moment occurred in the 1960s when an Indian company, Sipla, began manufacturing a generic version of Propranolol, a high blood pressure medication developed by the British company ICI Pharmaceuticals, because the patented drug was too expensive for India <a class="yt-timestamp" data-t="00:02:31">[00:02:31]</a>. Sipla's R&D head, Yusuf Hamid, justified his actions to then-Prime Minister Indira Gandhi, who, recognizing the merits, urged Parliament to modify drug patent laws <a class="yt-timestamp" data-t="00:02:57">[00:02:57]</a>.

## The Patent Act of 1970: Fostering Generic Production

This advocacy led to the passing of the Patent Act of 1970, which significantly revitalized the Indian pharmaceutical industry <a class="yt-timestamp" data-t="00:03:12">[00:03:12]</a>. The Act had two primary goals <a class="yt-timestamp" data-t="00:03:21">[00:03:21]</a>:
1.  To ensure low-cost access to drugs <a class="yt-timestamp" data-t="00:03:24">[00:03:24]</a>.
2.  To foster the development of an indigenous Indian pharmaceutical industry and encourage import substitution <a class="yt-timestamp" data-t="00:03:26">[00:03:26]</a>.

Prior Indian patent laws, last updated in 1872, were rooted in British IP law and protected products <a class="yt-timestamp" data-t="00:03:36">[00:03:36]</a>. The 1970 Act replaced this with a system that protected the *process* rather than the *product* <a class="yt-timestamp" data-t="00:03:53">[00:03:53]</a>. It also set shorter time limits for process patentsâ€”about five to seven years after filing, compared to the previous 15 years <a class="yt-timestamp" data-t="00:04:07">[00:04:07]</a>. Furthermore, if the Indian Patent Office deemed patents not to be used beneficially, it could compel patent holders to license them at a reasonable rate <a class="yt-timestamp" data-t="00:04:17">[00:04:17]</a>. This new system created vast opportunities for the Indian pharmaceutical industry by allowing for the reverse engineering of popular imported drugs <a class="yt-timestamp" data-t="00:04:31">[00:04:31]</a>.

## The Rise of Generics and Challenges (1970-1990)

The Patent Act of 1970 prompted managers and scientists from public sector laboratories to establish new firms <a class="yt-timestamp" data-t="00:07:32">[00:07:32]</a>. The number of pharmaceutical firms in India more than doubled between 1970 and 1980 <a class="yt-timestamp" data-t="00:07:40">[00:07:40]</a>. Initially, Indian companies primarily reverse-engineered existing drugs by making slight modifications to their manufacturing processes <a class="yt-timestamp" data-t="00:07:48">[00:07:48]</a>. This strategy, though seemingly derivative, enabled domestic companies to gain significant competence in pharmaceuticals <a class="yt-timestamp" data-t="00:08:44">[00:08:44]</a>.

By the late 1980s, Indian pharmaceutical companies could manufacture virtually any new molecule without needing the original innovator's recipes <a class="yt-timestamp" data-t="00:08:52">[00:08:52]</a>. The time gap between the introduction of original innovations and Indian generics steadily narrowed, demonstrating improved reverse-engineering capabilities <a class="yt-timestamp" data-t="00:09:02">[00:09:02]</a>. For example:
*   Ibuprofen, introduced globally in 1967, had an Indian generic six years later in 1973 <a class="yt-timestamp" data-t="00:09:15">[00:09:15]</a>.
*   Ciprofloxacin, introduced by Bayer in 1986, had an Indian generic in just three years <a class="yt-timestamp" data-t="00:09:26">[00:09:26]</a>.

By 2006, Indian companies supplied 95% of the country's drugs, signifying the success of import substitution <a class="yt-timestamp" data-t="00:09:56">[00:09:56]</a>.

However, the 1970 patent change had drawbacks:
*   The industry became high in volume but low in value <a class="yt-timestamp" data-t="00:10:08">[00:10:08]</a>.
*   With low barriers to entry and little capital needed, the number of pharmaceutical companies reached around 16,000 by 1990 <a class="yt-timestamp" data-t="00:10:17">[00:10:17]</a>.
*   Companies focused on producing many molecules cheaply, leading to extremely low margins and vast overcapacity <a class="yt-timestamp" data-t="00:10:27">[00:10:27]</a>.
*   The industry became highly fragmented, with up to 100 brands for a single molecule <a class="yt-timestamp" data-t="00:10:42">[00:10:42]</a>.
*   Due to a lack of resources, incentives, or protections, the domestic Indian pharmaceutical industry did not invest significantly in R&D and produced few new drugs <a class="yt-timestamp" data-t="00:10:53">[00:10:53]</a>.

By the 1990s, some 40% of Indian drug production was for export, but these were mostly low-value products, locking Indian companies out of more lucrative markets <a class="yt-timestamp" data-t="00:11:04">[00:11:04]</a>.

## TRIPS Agreement and the Shift Towards Innovation (Post-1992)

A major milestone in the industry's [[history_of_indias_pharmaceutical_industry | history]] was India's signing of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 1992 <a class="yt-timestamp" data-t="00:11:21">[00:11:21]</a>. TRIPS required the Indian government to amend its patent policies to align with international trade standards, recognizing product patents and granting exclusive marketing rights to new products <a class="yt-timestamp" data-t="00:11:37">[00:11:37]</a>. This agreement was highly controversial, splitting the domestic industry <a class="yt-timestamp" data-t="00:11:53">[00:11:53]</a>. However, the international trade community granted India until 2005 to prepare its drug industry, leading to gradual implementation of necessary changes, such as the exclusive marketing rights amendment in 1999 <a class="yt-timestamp" data-t="00:12:17">[00:12:17]</a>.

From 1992 to 2005, the industry underwent a monumental shift, moving away from its decades-old successful model towards a new, more profitable one <a class="yt-timestamp" data-t="00:13:35">[00:13:35]</a>.
*   **Investment in R&D**: A few firms, like Ranbaxy, Dr. Reddy's Laboratories (DRL), and Wockhardt, decided to invest in R&D, climb the value chain, and enter the drug discovery business <a class="yt-timestamp" data-t="00:12:52">[00:12:52]</a>. While the Indian pharmaceutical industry discovered only 13 new drug compounds from 1956 to 1987, that number was seven from 1991 to 2005 <a class="yt-timestamp" data-t="00:13:06">[00:13:06]</a>. Annual R&D spending accelerated from 4.9% before 1992 to 6.6% after 1992 <a class="yt-timestamp" data-t="00:13:19">[00:13:19]</a>. Indian institutions' pharmaceutical drug patents grew significantly:
    *   1990-1994: 9 patents <a class="yt-timestamp" data-t="00:13:40">[00:13:40]</a>
    *   1995-1998: 48 patents <a class="yt-timestamp" data-t="00:13:45">[00:13:45]</a>
    *   1999-2002: 227 patents <a class="yt-timestamp" data-t="00:13:48">[00:13:48]</a>
    The government also encouraged R&D through schemes, founding bodies to coordinate academic and commercial areas, and creating a pharmaceutical R&D support fund <a class="yt-timestamp" data-t="00:13:55">[00:13:55]</a>.
*   **Diversification and Strengthening the Value Chain**: Most Indian firms, recognizing the high cost and time commitment of drug discovery, explored other strategies to strengthen or diversify revenues <a class="yt-timestamp" data-t="00:14:12">[00:14:12]</a>.
    *   Some invested in R&D in drug-adjacent fields like drug delivery <a class="yt-timestamp" data-t="00:14:52">[00:14:52]</a>.
    *   Others expanded and strengthened parts of the value chain such as marketing and production <a class="yt-timestamp" data-t="00:15:01">[00:15:01]</a>.
    *   Many companies pursued strategic [[collaboration_with_global_suppliers | collaboration with multinationals]] <a class="yt-timestamp" data-t="00:15:07">[00:15:07]</a>. Zydus Cadila, for instance, engaged in deals with companies in France, Cuba, Switzerland, and the United States <a class="yt-timestamp" data-t="00:15:11">[00:15:11]</a>. Biocon's joint venture with the Cuban Center of Molecular Immunology helped it develop the first new monoclonal antibody treatment by an Indian pharmaceutical company <a class="yt-timestamp" data-t="00:15:30">[00:15:30]</a>.
    *   Some pursued mergers and acquisitions to scale up and match the size of Western multinationals <a class="yt-timestamp" data-t="00:15:43">[00:15:43]</a>.

## Global Competitiveness and Current Challenges

TRIPS significantly pushed India's pharmaceutical companies towards the export market <a class="yt-timestamp" data-t="00:16:01">[00:16:01]</a>. Once the industry met its IP regulation responsibilities, the global market became accessible <a class="yt-timestamp" data-t="00:16:09">[00:16:09]</a>. Today, India's generics industry is highly [[export_growth_and_international_competitiveness | internationally competitive]], aided by lower costs and expertise gained from fierce domestic competition <a class="yt-timestamp" data-t="00:16:15">[00:16:15]</a>. A favorable generic drug regulatory environment, such as the US Hatch-Waxman Act of 1984 which eased FDA approval for generics, also contributed <a class="yt-timestamp" data-t="00:16:27">[00:16:27]</a>.

Companies like Dr. Reddy's Laboratories and Marksans Pharma dramatically increased their export ratios <a class="yt-timestamp" data-t="00:16:39">[00:16:39]</a>:
*   Dr. Reddy's: 53% (2000-2005) to 74% (2012-2017) <a class="yt-timestamp" data-t="00:16:42">[00:16:42]</a>
*   Marksans Pharma: 21.2% (2000-2005) to 97.5% (2012-2017) <a class="yt-timestamp" data-t="00:16:53">[00:16:53]</a>

The industry's average export intensity grew by about 13% annually after the 2005 TRIPS implementation, leading to an almost eight-fold increase in size, with sales extending to North America, Africa, and Asia <a class="yt-timestamp" data-t="00:17:04">[00:17:04]</a>.

A significant concern for this export success is the Indian pharmaceutical industry's concurrent [[dependence_on_china_for_active_pharmaceutical_ingredients | dependence on China for active pharmaceutical ingredients]] (APIs), which are the most critical raw materials for finished drugs <a class="yt-timestamp" data-t="00:17:21">[00:17:21]</a>. India relies on China for 70% of its API imports <a class="yt-timestamp" data-t="00:17:40">[00:17:40]</a>. Imports of Chinese APIs, particularly antibiotics, have tripled since 2005 <a class="yt-timestamp" data-t="00:17:46">[00:17:46]</a>. India used to produce these domestically but lost the market to China in the 1990s due to products being 40% cheaper <a class="yt-timestamp" data-t="00:17:54">[00:17:54]</a>. Even with higher Chinese labor costs today, a 20% price gap remains <a class="yt-timestamp" data-t="00:18:03">[00:18:03]</a>. This weakness became apparent in 2020 when China's lockdowns caused stock shortages and export restrictions on certain ingredients <a class="yt-timestamp" data-t="00:18:11">[00:18:11]</a>. Geopolitical tensions between China and India further highlight the need for the Indian industry and government to implement new import substitution policies for APIs <a class="yt-timestamp" data-t="00:18:25">[00:18:25]</a>.

## Conclusion

India's pharmaceutical success has served as a model for other countries, which observed how the 1970 Indian Patent Act lowered drug costs and challenged multinational dominance <a class="yt-timestamp" data-t="00:18:41">[00:18:41]</a>. Ironically, as India moved away from process-based patents, other nations began adopting them <a class="yt-timestamp" data-t="00:18:54">[00:18:54]</a>. The Indian pharmaceutical industry's current standing is a testament to its adaptability and the strategic application and re-application of IP rights, exemplifying market-driven reform spurred by environmental changes <a class="yt-timestamp" data-t="00:19:03">[00:19:03]</a>. Despite remaining concerns, India's pharmaceutical industry is poised to play a crucial role in addressing global health issues in the future <a class="yt-timestamp" data-t="00:19:31">[00:19:31]</a>.